Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 27 for “"bispecific"”.
-
Bispecific Ligand Conjugate Immunotherapy of Choroid Plexus Brain Tumors
… work may offer insights into the application of bispecific ligand conjugates to the treatment of human cancers. Application of this design includes all tumors that express folate receptors, but additional ligands may be used to target other tumor varieties.
-
Targeting of adenovirus serotype 5 infectivity to EGFRvIII-expressing cells using a bispecific CAR-scFv.
… binding affinities of its composite subunits (bispecificity) as strongly as the two independent proteins do for the knob domain and EGFRvIII, respectively. Additionally, a U87MG EGFRvIII transduced cell line, as opposed to its parental U87MG cell line, showed increased infectivity by adenovirus …
-
Development of a novel antibody molecule for redirected T cell immunity to tumor cells: The bispecific single chain antibody
… to specifically kill tumor cells by the use of a bispecific antibody. This approach is achieved through the use of bispecific antibodies that bind the T cell and the tumor cell, triggering the specific elimination of the tumor cell. Despite the success of bispecific antibodies and emergence into …
-
DEVELOPMENT OF BISPECIFIC T CELL ENGAGERS TARGETING CARBONIC ANHYDRASE 9 FOR THE IMMUNE THERAPY OF CLEAR CELL RENAL CELL CARCINOMA
… for advanced cases. Yet to reach patients are bispecific T cell engaging antibodies (BTEs) that target T cell cytotoxicity to tumors by simultaneously binding T cell and cancer antigens, for which exist multiple design formats. However, there are limited comparative characterizations among …
-
GENERATION OF SYNTHETIC ANTIBODIES AS POTENTIAL THERAPEUTICS TO BLOCK IL3–MEDIATED INNATE IMATINIB RESISTANCE IN CHRONIC MEYLOID LEUKEMIA
… anti–IL3Rβ–IL3Rβ bivalent and anti–IL3Rβ–IL3Rα bispecific antigen binding fragments (Fabs) to enhance targeting of CML cells. SpyCatcher-SpyTag system was used to join IL3Rα / IL3Rβ mono–Fabs by a covalent bond. The bivalent and bispecific Fab formats against IL3Rα, IL3Rβ, or IL3Rα and IL3Rβ …
-
biological treatment options of multiple myeloma
… antigen receptor T cells, T cell engaging bispecific antibodies, antibody-drug conjugates along with steroids, and immunomodulatory therapies. Bortezomib, Carfilzomib, and Ixazomib are examples of proteasome inhibitors. Bortezomib is the predominant choice in treatment regimens. The basic …
-
Model systems for the retargeting of T cell-mediated immunity to tumor antigens
… for accomplishing this is the construction of a bispecific antibody which binds a tumor cell antigen and a T-cell receptor, bringing the T cell into contact with the tumor cell and activating the T cell to destroy the tumor cell.
-
BiTEs and CAR-Ts : immunotherapy in childhood B-cell acute lymphoblastic leukemia
… is ineffective. Immunotherapy, specifically bispecific T-cell engaging antibody therapy and chimeric antigen receptor T-cell therapy, has proven an effective treatment for relapsed and refractory B-cell acute lymphoblastic leukemia in children. These new modalities, however, have also …
-
Construction and characterisation of anti-tumour antibody-based proteins for use in diagnostics and therapeutics
… second next-generation antibody format is the bispecific antibody (biMab) - an antibody with the ability to bind to two independent epitopes. In this study IgG constructs with single point mutations were engineered to enable the formation of biMabs using DuoBody technology. Here, the central …
-
Study of a Transferrin Receptor Brain Shuttle for the Delivery of Nanobodies Against GABAA Receptors
… receptor and GABAAR in cell-based assays. For bispecific 8D3-Nb molecules, retention of Nb binding for GABAAR was orientation specific, although all formats retained binding affinities for TfR in the nanomolar range. Affinity for TfR was similar across unconjugated 8D3 formats, regardless of …
-
Epiregulin as a Novel Target for Antibody-Drug Conjugate Development for the Treatment of Colorectal Cancer
… first EREG-targeted ADC, and developed a novel bispecific Ab for future ADC development. Genetic ablation of EREG in a KRAS mutant CRC cell line resulted in a decrease in migration, invasion, and tumor growth. Further, we produced a highly specific EREG mAb, H231, that exhibited strong binding …
-
Overcoming T Cell Tolerance Against Endogenous Choroid Plexus Tumors Using a Combination Immunotherapy
… of costimulation through an anti-CD28/Folate bispecific conjugate, PV-1 Fab/Folate, further enhanced survival and dramatically slowed tumor growth. Furthermore, proliferating CD8 T cells were found in tumors of treated animals. However, upon treatment withdrawal, tumors rapidly progressed and …
-
De novo synthesis of high purity CD3 epsilon peptides utilizing SUMO expression system in bacteria
… the monoclonal antibodies, T cell-dependent bispecific antibodies directly target tumor cells for cancer treatment, they kill tumor cells by activating T cells through binding to the CD3 (cluster of differentiation 3) receptor on T cells. Many anti-CD3 antibodies bind to the surface exposed …
-
Met inhibitors στον μη μικροκυτταρικό καρκίνο του πνεύμονα / Met inhibitors in non–small cell lung cancer
… προσεγγίσεις όπως antibody–drug conjugates, bispecific antibodies και συνδυαστικές στρατηγικές αναμένεται να διευρύνουν περαιτέρω το θεραπευτικό πεδίο, ενώ η ολοκληρωμένη μοριακή χαρτογράφηση παραμένει κρίσιμη για την ορθή επιλογή ασθενών.
-
Efficacy of novel immunotherapeutic strategies targeting L1CAM in pancreatic cancer
… dimer (SG3199)) as payload and a bispecific antibody targeting L1CAM on tumor cells and CD3 on T cells in different preclinical PDAC models. Both L1CAM-ADC led to a L1CAM specific reduction in tumor cell growth of up to 60% in 2D PDAC cell models. Application of L1CAM-ADC as …
-
Interrogating structure-function relationships in the pathogenesis and treatment of human disease : insights into the development of therapeutics for emergent tropical viruses
… to generate C867, a novel asymmetric IgG bispecific antibody against Zika virus. This antibody has high bispecific purity, maintains in vitro potency, and given its non-overlapping epitopes, has a higher requirement for antigen escape. Taken together, the tools, frameworks, and …
-
MODIFICATION OF VESICULAR STOMATITIS VIRUS G PROTEIN FOR TARGETED GENE DELIVERY INTO PSCA-POSITIVE TUMOR CELLS
… VSV-G protein and PSCA on the tumor cell. These bispecific nanobeads allowed the recruitment of mutant retroviral particles to the PSCApositive cells. Our results point out the potential of these mutant retroviral particles in targeted gene delivery. Further studies will be necessary to assess …
-
The Initial Events of T-Cell Activation in Realistic Model Systems
… showed T cells also responded to ImmTAC, a bispecific immunotherapeutic, presented on APCs via small contact zones during all stages of interaction. The results presented show the importance of small contact zones in the initial events of T-cell activation and provide a way to image and …
-
Targeting the tight junction : immunotherapy of colon cancer
… tumor targeting therapy utilizing a novel bispecific antibody which recognizes both the A33 antigen and a small molecule radiometal chelate. Following these studies, several protein engineering techniques are presented. First, a new method of conducting de novo protein engineering utilizing …
Page 1 of 2